SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

02 Feb 2024 Evaluate
The revenue slipped marginally during the December 2023 quarter. A decline of about Rs. 1752.00 millions was observed as compared to Rs. 1828.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended December 2023 is Rs. -24.00 millions as compared to Net Loss of Rs. -59.00 millions of corresponding quarter ended December 2022The company reported a good operating profit of 183.00 millions compared to 59.00 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 1752.00 1828.00 -4.16 5789.00 6103.00 -5.15 8101.20 7257.30 11.63
Other Income 190.00 78.00 143.59 533.00 1242.00 -57.09 1378.90 1261.60 9.30
PBIDT 183.00 59.00 210.17 576.00 1252.00 -53.99 1411.10 1326.20 6.40
Interest 83.00 55.00 50.91 218.00 128.00 70.31 185.20 109.90 68.52
PBDT 100.00 4.00 2400.00 358.00 1124.00 -68.15 1225.90 1216.30 0.79
Depreciation 123.00 116.00 6.03 356.00 319.00 11.60 432.50 369.10 17.18
PBT -23.00 -112.00 -79.46 2.00 805.00 -99.75 793.40 847.20 -6.35
TAX 1.00 -53.00 -101.89 11.00 -2.00 -650.00 294.60 42.30 596.45
Deferred Tax 5.00 -53.00 -109.43 11.00 -146.00 -107.53 156.40 -100.50 -255.62
PAT -24.00 -59.00 -59.32 -9.00 807.00 -101.12 498.80 804.90 -38.03
Equity 159.00 159.00 0.00 159.00 159.00 0.00 159.30 159.30 0.00
PBIDTM(%) 10.45 3.23 223.62 9.95 20.51 -51.50 17.42 18.27 -4.68

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×